Form 4: Lexeo Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, sold 1,486 shares of common stock to cover tax obligations related to the release of restricted stock units.
Summary
- On February 19, 2025, Sandi See Tai, the Chief Development Officer of Lexeo Therapeutics, sold 1,486 shares of the company's common stock.
- The sale was executed at a price of $4.413 per share.
- This transaction was conducted to cover tax obligations arising from the release of restricted stock units (RSUs).
- Following the transaction, Sandi See Tai still beneficially owns 53,889 shares, which includes 51,218 RSUs.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine transaction related to tax obligations and doesn't necessarily reflect a positive or negative outlook on the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies.
Stakeholder Impact
- The sale has a minimal impact on shareholders as it's a small transaction related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 02/19/2025 | Date of stock sale transaction |
| 02/21/2025 | Date of signature on the Form 4 filing |
Keywords
Lexeo Therapeutics, Sandi See Tai, Chief Development Officer, stock sale, Form 4, restricted stock units, tax obligations, LXEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.